HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset...
MONTREAL, Nov. 08, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation,...
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase...
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it...
PGX processing unit to be installed at Agri-Food Discovery Place of University of AlbertaAlginate and yeast beta glucan to be...
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE)...
Efficacy of OCA vs. placebo and external controls accepted as a late-breaker poster HEROES-US data to be presented in oral...
Table: Antiviral Effect of MAU868 vs. Placebo at Week 36 Table: Antiviral Effect of MAU868 vs. Placebo at Week 36New...
Data presented in late-breaking oral presentation demonstrated deep and consistent TTR reduction following a single dose of NTLA-2001 in patients...
- New analysis of cohort 7 data using a three-reader pathologist panel showed that 6/19 patients scored as having fibrosis...
Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022...
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase...
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Fuss Brands Corp. (OTC Markets: FBDS) announced today the signing of an...
THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022...
TORONTO, Nov. 04, 2022 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) (OTCQX:VHIBF) is pleased to announce...
SAN LEANDRO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development...
SINGAPORE and BETHESDA, Md., Nov. 04, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing...
EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial...
Data demonstrated treatment with TERN-501 resulted in time- and dose-dependent increases in sex hormone binding globulin (SHBG), a key marker...
ALG-055009, a THR-β agonist drug candidate in development as a treatment for NASH, demonstrated dose-dependent reductions in several atherogenic lipids and a...